Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

34 results about "Area under curve" patented technology

Multi-parameter magnetic resonance image based prostate cancer computer auxiliary identification system

The invention discloses a multi-parameter magnetic resonance image based prostate cancer computer auxiliary identification system and method. The multi-parameter magnetic resonance image based prostate cancer computer auxiliary identification system comprises three portions of an image preprocessing module, a parameter processing module and a prediction and evaluation module. According to the multi-parameter magnetic resonance image based prostate cancer computer auxiliary identification system, the characteristics of a T2 weighted image, a diffusion weighted image and a dynamic enhanced image are comprehensively utilized and the purpose of the identification of the prostate cancer focus is achieved through an artificial neural network structure; the ROC (Receiver Operating Characteristic) area under curve of the peripheral zone of prostate of the system is 0.931 and the identification accuracy is 0.887 and the ROC area under curve in the central gland is 0.909 and the identification accuracy is 0.915 through a test; the image information obtained through the conventional magnetic resonance imaging scanning sequence scanning sequence can be well integrated, quantitative parameters in the images are utilized in a maximum mode, and the identification result of the prostate cancer is objectively provided; the operation is simple and convenient, the reference can be intuitively provided for doctors, and the important basis is provided for the subsequent diagnosis scheme.
Owner:PEKING UNIV

Link prediction method in large-scale microblog heterogeneous information network

The invention relates to the field of Internet technology, and provides a link prediction method in a large-scale microblog heterogeneous information network. The link prediction method comprises the following steps: filtering users according to preset strategy; extracting a plurality of links from the network, wherein a positive example set is ET, and a negative example set is EF; calculating the characteristics of all nodes in ETUEF and the characteristics of the links in an E-ET-EF network, and converting the characteristics of the nodes into the characteristics of link relations; dividing the EFUET into a training set, a verification set and a test set, training models on the training set, selecting model hyper-parameters with the optimal prediction result on the verification set to obtain a final model h theta (x) and a threshold value theta; putting any link relation in the test set into the model, so that the probability P generated by the link relation can be obtained. Experiments show that the area under curve and F value of the method provided by the invention are obviously improved compared with a method based on local information similarity and path similarity, and the method has higher maximum K accuracy rate stability.
Owner:SICHUAN UNIV

Method for evaluating stable state of flora in excrement sample and application of method in colorectal cancer screening

PendingCN108690864ALow costGood Gut Health ScreeningMicrobiological testing/measurementMicroorganism based processesClostridium leptumFeces
The invention relates to a method for calculating a flora balanced relation index in an individual excrement sample, and an application of the method in screening, diagnosis or auxiliary diagnosis incolorectal cancer (CRC). By extracting bacteria in excrement during DNA sequencing, the types and quantity characteristics of the bacteria can be obtained, and a CRC diagnosis by taking quantity ratiocharacteristic of a plurality of bacteria as a base is carried out. Compared with the methods used in clinical diagnosis or noninvasive screening of CRC with an applied patent, the method is completely noninvasive, and can realize accurate diagnosis of CRC. The analysis result displays that a ratio of fusobacterium nucleatum Fn to bifidobacteria Bb quantity (Fn/Bb) has high susceptibility and specificity on CRC screening, which can respectively reach 84.6% and 92.3% (AUC=0.911). the ratio of fusobacterium nucleatum Fn to clostridium leptum Fp (Fn/Fp) quantity is combined to increase the diagnosis value on CRC, and the Area Under Curve (AUC) of a subject work characteristic curve can reach 0.943. In addition, combination of Fn/Bb and Fn/Fp quantity ratio for screening I-stage CRC has 60% of specificity and 90% of sensitivity.
Owner:SUN YAT SEN UNIV

Traditional Chinese compound for curing central obesity and nonalcoholic fatty liver disease and preparation method thereof

InactiveCN101530517AReduce abdominal circumferenceReduced CT ratioMetabolism disorderDigestive systemInflammatory factorsTreatment effect
The invention discloses a traditional Chinese compound preparation for curing nonalcoholic fatty liver and central obesity and is characterized in that the compound preparation is prepared by adding medicinal excipient to the extractives of milk veteh, rhizoma coptidis, prepared rhubarb, raw cattail pollen and herba artemisiae capillaris, wherein the weight mixture ratio of milk veteh, rhizoma coptidis, prepared rhubarb, raw cattail pollen and herba artemisiae capillaris is 1-4:1:1-3:1-3:1-3. Proved by clinical trial, the drug combination of the invention can reduce the abdominal perimeter of patients, lower the AUC (area under curve) of triglyceride after dinner, improve the CT specific value of liver and spleen and bring down the transaminase level of liver with evident treatment effect. Verified by clinical research, the compound can obviously increase the insulin sensitivity of patients, lower inflammatory factor level and improve fibrinolysis-blood clotting function. Shown by experimental research, the drug of the invention can enhance the sensitivity of fat and muscle cells to insulin and has significant value in treating nonalcoholic fatty liver and central obesity which take insulin resistance as fundamental pathological link.
Owner:王文健

Metabolic marker group for diagnosing coronary heart disease

The invention discloses a metabolic marker group for diagnosing a coronary heart disease. The metabolic marker group comprises one or more of citramalic acid, methionine, taurine, malic acid, phenylalanine and linoleic acid. In a ROC (receiver operating characteristic) curve evaluation method, under the condition that the AUC (area under curve) is larger than 0.5, the closer the AUC is to 1, the better the diagnosis effect is. A metabolic marker has lower accuracy when the AUC is 0.5-0.7, has certain accuracy when the AUC is 0.7-0.9 and has higher accuracy when the AUC is 0.9 or larger. Verification proves that when the single metabolic marker in the metabolic marker group is used for diagnosing and distinguishing patients with the coronary heart disease from subjects with normal coronary arteries, or diagnosing and distinguishing the patients with the coronary heart disease from patients with coronary atherosclerosis, the AUCs are all 0.7 or larger; when a plurality of the metabolic markers are used in combination, the AUC is closer to 1 than that when the single metabolic marker is used, so that the diagnosis effect is better; when six metabolic markers are used in combination, the AUC is closest to 1, and diagnosing and distinguishing effects are the best.
Owner:苏州帕诺米克生物科技有限公司

Method and device for evaluating accuracy of model for predicting silicon content in hot metal of blast furnace

The invention provides a method and device for evaluating the accuracy of a model for predicting the silicon content in hot metal of a blast furnace. The method comprises the steps of: obtaining working condition parameters influencing the silicon content in the hot metal of the blast furnace in historical data, a silicon content measurement value and a silicon content prediction value of a silicon content prediction model to be evaluated, and, according to a trained accuracy prediction model, classifying the prediction result accuracy of the silicon content prediction value, so that a first evaluation classification result is obtained; classifying the accuracy of the silicon content prediction value according to the silicon content measurement value, so that a second evaluation classification result is obtained; and, obtaining a true positive rate TPR and a false positive rate FPR based on the first evaluation result and the second evaluation result, and evaluating the reliability ofthe silicon content prediction model through a receiver operating characteristic curve ROC. A ROC is drawn through a prediction result; the performance of the prediction model can be overall judged through the indexes, such as an AUC (Area Under Curve); and thus, production can be guided by selection of a proper prediction model for a site.
Owner:CENT SOUTH UNIV

Time-varying constraint electroencephalogram or magnetoencephalogram source tracing method based on functional magnetic resonance imaging

The invention provides a time-varying constraint electroencephalogram or magnetoencephalogram source tracing method based on functional magnetic resonance imaging. The method comprises the steps thatan electroencephalogram or magnetoencephalogram signal is recorded and traced, an initial electroencephalogram or magnetoencephalogram source intensity value is obtained, and an electroencephalogram or magnetoencephalogram source intensity matrix is obtained on the basis; functional magnetic resonance imaging data is recorded, a functional magnetic resonance imaging activation image is obtained onthe basis of the functional magnetic resonance imaging data, and then a functional magnetic resonance imaging weight matrix is obtained; a covariance matrix of a source is obtained according to the functional magnetic resonance imaging weight matrix and the electroencephalogram or magnetoencephalogram source intensity matrix, and the covariance matrix of the source is set to be changed along withtime; the interactive communication effect and the area-under-curve of a normalization part are calculated according to the initial electroencephalogram or magnetoencephalogram source intensity value, and the covariance matrix of the source is corrected on the basis; source tracing is carried out according to the corrected covariance matrix of the source, a final electroencephalogram or magnetoencephalogram source intensity value is obtained, and source tracing is completed.
Owner:PEKING UNIV

Bioequivalence evaluating method for medicines for reducing blood sugar by using pharmacodynamics as index

The invention provides a bioequivalence evaluating method for medicines for reducing blood sugar by using pharmacodynamics as an index, and relates to a three-cycle three-cross bioequivalence evaluating method by using pharmacodynamics parameters of blood sugar concentration as an evaluating index, wherein the medicines are mainly alpha-glycosidase inhibitor type medicines. Examines are divided into three groups randomly, and are respectively subjected to medicine test of reference medicines, contrast medicines and vacancy medicines at the three-cycle experiment stage, and then are subjected to glucose load experiment, and besides, blood samples within 4 hours are collected, and concentration determination results of glucose in serum are recorded as the blood sugar concentration. Evaluating parameters include the largest blood sugar concentration difference (delta Cmax) of the examinees under the condition of being subjected to medicine test of the reference medicines or the contrast medicines and the vacancy medicines; and the 2-4-hoursblood sugar concentration-time area under curve difference (delta AUC0-n) of the examinee under the condition of being subjected to medicine test of reference medicines or contrast medicines or vacancy medicine. The judgment standard lies in that the equivalence standard lies in that the 90% confidence interval of the group geometric mean valueratio of the delta Cmax to the delta AUC0-n in the evaluating parameters of a test preparation and the contrast medicines needs to fall in the range of 80%-125%.
Owner:金日制药(中国)有限公司

Traditional Chinese compound for curing central obesity and nonalcoholic fatty liver disease and preparation method thereof

InactiveCN101530517BReduce abdominal circumferenceReduced CT ratioMetabolism disorderDigestive systemInflammatory factorsClinical trial
The invention discloses a traditional Chinese compound preparation for curing nonalcoholic fatty liver and central obesity and is characterized in that the compound preparation is prepared by adding medicinal excipient to the extractives of milk veteh, rhizoma coptidis, prepared rhubarb, raw cattail pollen and herba artemisiae capillaris, wherein the weight mixture ratio of milk veteh, rhizoma coptidis, prepared rhubarb, raw cattail pollen and herba artemisiae capillaris is 1-4:1:1-3:1-3:1-3. Proved by clinical trial, the drug combination of the invention can reduce the abdominal perimeter ofpatients, lower the AUC (area under curve) of triglyceride after dinner, improve the CT specific value of liver and spleen and bring down the transaminase level of liver with evident treatment effect. Verified by clinical research, the compound can obviously increase the insulin sensitivity of patients, lower inflammatory factor level and improve fibrinolysis-blood clotting function. Shown by experimental research, the drug of the invention can enhance the sensitivity of fat and muscle cells to insulin and has significant value in treating nonalcoholic fatty liver and central obesity which take insulin resistance as fundamental pathological link.
Owner:王文健
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products